Lilly Leaps Into China Broad Diabetes Market, Echoing Sanofi, Novo
This article was originally published in PharmAsia News
Executive Summary
Signaling a new direction, Lilly is embracing China's vast county hospital market for its diabetes care products through a new access initiative, following in the footsteps of rivals Sanofi and Novo Nordisk but with a bolder and broader approach.